Alexza Pharmaceuticals

Alexza Pharmaceuticals, located in Mountain View, CA, is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. ADASUVE is the first and only inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. ADASUVE combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects. Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza's commercial partner for ADASUVE in the United States. Grupo Ferrer Internacional SA is Alexza's commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries. ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Company Growth (employees)
Type
Public
HQ
Mountain View, US
Size (employees)
27 (est)
Website
alexza.com
Alexza Pharmaceuticals is headquartered in Mountain View, US

Key People at Alexza Pharmaceuticals

Leighton Read

Leighton Read

Director
Darl Moreland

Darl Moreland

Vice President, Quality

Alexza Pharmaceuticals Office Locations

Alexza Pharmaceuticals has an office in Mountain View
Mountain View, US (HQ)
2091 Stierlin Ct

Alexza Pharmaceuticals Data and Metrics

Alexza Pharmaceuticals Financial Metrics

Alexza Pharmaceuticals's revenue was reported to be $5 m in FY, 2015 which is a 10% decrease from the previous period.
$, USD

Revenue (FY, 2015)

5 m

Revenue growth (FY, 2014 - FY, 2015), %

(10%)

Gross profit (FY, 2015)

(16.1 m)

Gross profit margin (FY, 2015), %

(320%)

Net income (FY, 2015)

(21.3 m)

EBIT (FY, 2015)

(40 m)

Cash (31-Dec-2015)

7.8 m
$, USDFY, 2013FY, 2014FY, 2015

Revenue

47.8 m5.6 m5 m

Revenue growth, %

(88%)(10%)

Cost of goods sold

11.2 m15.9 m21.1 m

Gross profit

36.6 m(10.4 m)(16.1 m)

Gross profit Margin, %

77%(186%)(320%)

Operating expense total

34.9 m27.1 m45.1 m

EBIT

1.8 m(37.5 m)(40 m)

EBIT margin, %

4%(674%)(796%)

Interest expense

1.5 m7.4 m8.4 m

Net Income

(39.6 m)(36.7 m)(21.3 m)
$, USDFY, 2013FY, 2014FY, 2015

Cash

17.3 m15.2 m7.8 m

Inventories

1.5 m3.1 m3.2 m

Current Assets

30.9 m41.8 m11 m

PP&E

15 m14 m3.3 m

Total Assets

47.1 m61.6 m14.7 m

Accounts Payable

3.8 m1.8 m442 k

Current Liabilities

14.9 m11.5 m58.2 m

Additional Paid-in Capital

350.3 m359.3 m360.6 m

Retained Earnings

(374.2 m)(411 m)(432.3 m)

Total Equity

(51.7 m)

Financial Leverage

-1.2 x
$, USDFY, 2013FY, 2014FY, 2015

Net Income

(39.6 m)(36.7 m)(21.3 m)

Depreciation and Amortization

3.3 m3.4 m3 m

Inventories

(601 k)(822 k)(1.2 m)

Accounts Payable

1.6 m(2 m)(1.4 m)

Cash From Operating Activities

(612 k)(41.5 m)(31.9 m)

Purchases of PP&E

(1.8 m)(2.4 m)(58 k)

Cash From Investing Activities

(10.3 m)(13.5 m)19.5 m

Cash From Financing Activities

10.5 m52.9 m5 m

Interest Paid

863 k4.2 m2.8 m
$, USDY, 2015

Revenue/Employee

50.5 k

Alexza Pharmaceuticals News and Updates

Alexza Pharmaceuticals Company Life and Culture

You may also be interested in